不进行血浆置换治疗血栓性血小板减少性紫癜：耶和华见证人的经验。
Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah's Witness experience.
作者信息
George James N, Sandler Steven A, Stankiewicz Joanna
机构信息
Department of Medicine, College of Medicine, and.
Department of Biostatistics and Epidemiology, College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, OK; and.
出版信息
Blood Adv. 2017 Oct 30;1(24):2161-2165. doi: 10.1182/bloodadvances.2017012351. eCollection 2017 Nov 14.
Abstract
TTP in Jehovah's Witness patients has been managed successfully without PEX.This experience, plus new TTP treatments, may make it possible for patients who are not Jehovah's Witnesses to avoid PEX in the future.
摘要
耶和华见证人的患者在没有进行血浆置换的情况下成功治疗了血栓性血小板减少性紫癜。这一经验，再加上新的血栓性血小板减少性紫癜治疗方法，可能使非耶和华见证人的患者未来也有可能避免进行血浆置换。
相似文献
1
Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah's Witness experience.不进行血浆置换治疗血栓性血小板减少性紫癜：耶和华见证人的经验。
Blood Adv. 2017 Oct 30;1(24):2161-2165. doi: 10.1182/bloodadvances.2017012351. eCollection 2017 Nov 14.
2
Successful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange.在一名耶和华见证会成员中成功管理血栓性血小板减少性紫癜且未进行血浆置换
J Clin Apher. 2015 Feb;30(1):46-9. doi: 10.1002/jca.21325. Epub 2014 Apr 30.
3
Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah's Witness patients: A review of reported cases.血栓性血小板减少性紫癜管理中对耶和华见证人患者的治疗方法：病例报告回顾。
Transfus Apher Sci. 2023 Aug;62(4):103706. doi: 10.1016/j.transci.2023.103706. Epub 2023 Mar 21.
4
Successful management of a Jehovah's Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange.成功治疗一名患有血栓性血小板减少性紫癜且不愿接受治疗性血浆置换的耶和华见证会成员。
J Clin Apher. 2007;22(6):330-2. doi: 10.1002/jca.20150.
5
Survival of a Jehovah's Witness with thrombotic thrombocytopenic purpura without using plasma: A case report and review of the literature.一名耶和华见证会信徒在未使用血浆的情况下患血栓性血小板减少性紫癜的存活病例报告及文献综述
J Clin Apher. 2019 Oct;34(5):623-630. doi: 10.1002/jca.21710. Epub 2019 May 22.
6
Successful Management of Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness: An Individualized Approach With Joint Decision-Making.耶和华见证人中血栓性血小板减少性紫癜的成功管理：一种联合决策的个体化方法。
J Patient Exp. 2020 Feb;7(1):8-11. doi: 10.1177/2374373519829902. Epub 2019 Feb 14.
7
Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.一名耶和华见证会信徒患免疫介导的血栓性血小板减少性紫癜——联合体外免疫吸附、卡泊单抗、类固醇和利妥昔单抗的疗效
Clin Case Rep. 2022 May 20;10(5):e05902. doi: 10.1002/ccr3.5902. eCollection 2022 May.
8
Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient.聚乙二醇化牛羧基血红蛋白在一名血栓性血小板减少性紫癜患者中的应用。
Transfus Med. 2017 Aug;27(4):300-302. doi: 10.1111/tme.12407. Epub 2017 Apr 12.
9
Caplacizumab Without Plasma Exchange for Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness.在一名耶和华见证人中使用卡泊单抗而非血浆置换治疗血栓性血小板减少性紫癜
Am J Ther. 2023;30(5):e502-e505. doi: 10.1097/MJT.0000000000001522. Epub 2022 May 26.
10
To treat or not to treat: a rare case of pseudo-thrombotic thrombocytopenic purpura in a Jehovah's Witness.治疗还是不治疗：一名耶和华见证会信徒患假性血栓性血小板减少性紫癜的罕见病例
Transfusion. 2016 Jan;56(1):160-3. doi: 10.1111/trf.13285. Epub 2015 Sep 12.
引用本文的文献
1
Separate (Asynchronous) Therapeutic Plasma Exchange (TPE) and Plasma Transfusion in the Patient with Severe TPE Complications: A Case Report.重度治疗性血浆置换（TPE）并发症患者的单独（异步）治疗性血浆置换（TPE）与血浆输注：病例报告
Int J Hematol Oncol Stem Cell Res. 2025 Jan 1;19(1):75-80. doi: 10.18502/ijhoscr.v19i1.17827.
2
Immune-mediated thrombotic thrombocytopenic purpura in a Jehovah's Witness - Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab.一名耶和华见证会信徒患免疫介导的血栓性血小板减少性紫癜——联合体外免疫吸附、卡泊单抗、类固醇和利妥昔单抗的疗效
Clin Case Rep. 2022 May 20;10(5):e05902. doi: 10.1002/ccr3.5902. eCollection 2022 May.
3
Complete recovery of deep venous thrombosis from Coombs (+) thrombotic thrombocytopenic purpura: case report.库姆斯试验阳性的血栓性血小板减少性紫癜所致深静脉血栓形成完全康复：病例报告
J Cardiothorac Surg. 2022 Mar 21;17(1):43. doi: 10.1186/s13019-022-01789-8.
4
Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated With Combined Therapy.病例报告：两例采用联合疗法治疗的儿童血栓性血小板减少性紫癜
Front Pediatr. 2021 Nov 2;9:743206. doi: 10.3389/fped.2021.743206. eCollection 2021.
5
Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management.血栓性血小板减少性紫癜：病理生理学、诊断与管理
J Clin Med. 2021 Feb 2;10(3):536. doi: 10.3390/jcm10030536.
6
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜患者临床护理的良好实践声明（GPS）
J Thromb Haemost. 2020 Oct;18(10):2503-2512. doi: 10.1111/jth.15009. Epub 2020 Sep 11.
7
Successful Management of Thrombotic Thrombocytopenic Purpura in a Jehovah's Witness: An Individualized Approach With Joint Decision-Making.耶和华见证人中血栓性血小板减少性紫癜的成功管理：一种联合决策的个体化方法。
J Patient Exp. 2020 Feb;7(1):8-11. doi: 10.1177/2374373519829902. Epub 2019 Feb 14.
8
The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective.血栓性血小板减少性紫癜的显著多样性：一个视角。
Blood Adv. 2018 Jun 26;2(12):1510-1516. doi: 10.1182/bloodadvances.2018018432.
本文引用的文献
1
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.血栓性血小板减少性紫癜：1995年至2015年的诊断标准、临床特征及长期预后
Blood Adv. 2017 Apr 6;1(10):590-600. doi: 10.1182/bloodadvances.2017005124. eCollection 2017 Apr 11.
2
Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient.聚乙二醇化牛羧基血红蛋白在一名血栓性血小板减少性紫癜患者中的应用。
Transfus Med. 2017 Aug;27(4):300-302. doi: 10.1111/tme.12407. Epub 2017 Apr 12.
3
Association of immune globulin intravenous and thromboembolic adverse events.静脉注射免疫球蛋白与血栓栓塞不良事件的关联。
Am J Hematol. 2017 Apr;92(4):E44-E45. doi: 10.1002/ajh.24644. Epub 2017 Feb 13.
4
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.卡普雷珠单抗治疗获得性血栓性血小板减少性紫癜。
N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533.
5
Successful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange.在一名耶和华见证会成员中成功管理血栓性血小板减少性紫癜且未进行血浆置换
J Clin Apher. 2015 Feb;30(1):46-9. doi: 10.1002/jca.21325. Epub 2014 Apr 30.
6
ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates.血浆源性因子 VIII/von Willebrand 因子浓缩物中的 ADAMTS13 含量。
Am J Hematol. 2013 Oct;88(10):895-8. doi: 10.1002/ajh.23527. Epub 2013 Aug 30.
7
Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features.与严重获得性 ADAMTS13 缺乏相关的血栓性血小板减少性紫癜的儿童和成人：发病率、人口统计学和临床特征比较。
Pediatr Blood Cancer. 2013 Oct;60(10):1676-82. doi: 10.1002/pbc.24612. Epub 2013 Jun 1.
8
Successful treatment of congenital TTP with a novel approach using plasma-derived factor VIII.采用源自血浆的凝血因子 VIII 的新方法成功治疗先天性血栓性血小板减少性紫癜。
J Pediatr Hematol Oncol. 2013 Oct;35(7):551-3. doi: 10.1097/MPH.0b013e3182755c38.
9
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.一项评估利妥昔单抗联合血浆置换治疗急性获得性血栓性血小板减少性紫癜的安全性和有效性的 2 期研究。
Blood. 2011 Aug 18;118(7):1746-53. doi: 10.1182/blood-2011-03-341131. Epub 2011 Jun 2.
10
Survival and relapse in patients with thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜患者的生存和复发。
Blood. 2010 Feb 25;115(8):1500-11; quiz 1662. doi: 10.1182/blood-2009-09-243790. Epub 2009 Dec 23.
Zotero 插件